Compare DVAX & DFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DVAX | DFIN |
|---|---|---|
| Founded | 1996 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2004 | N/A |
| Metric | DVAX | DFIN |
|---|---|---|
| Price | $15.63 | $55.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $26.50 | ★ $63.50 |
| AVG Volume (30 Days) | ★ 5.6M | 235.2K |
| Earning Date | 02-19-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.12 |
| Revenue | $330,514,000.00 | ★ $750,800,000.00 |
| Revenue This Year | $24.63 | N/A |
| Revenue Next Year | $15.85 | $4.20 |
| P/E Ratio | ★ N/A | $49.20 |
| Revenue Growth | ★ 26.73 | N/A |
| 52 Week Low | $9.20 | $37.80 |
| 52 Week High | $15.73 | $69.93 |
| Indicator | DVAX | DFIN |
|---|---|---|
| Relative Strength Index (RSI) | 85.75 | 77.14 |
| Support Level | $15.57 | $44.89 |
| Resistance Level | $15.73 | $50.21 |
| Average True Range (ATR) | 0.06 | 1.74 |
| MACD | -0.05 | 0.84 |
| Stochastic Oscillator | 70.83 | 93.67 |
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.